The Impact of Diabetes Remission on Aging
Key claim: A prospective Chinese real-world cohort will test whether type 2 diabetes remission slows epigenetic aging, primarily via DunedinPACE, versus non-remitters.
Abstract
This study is a real-world, prospective clinical cohort study. It will enroll Chinese patients with type 2 diabetes. The aim is to assess the changes in aging biomarkers, primarily DunedinPACE, from baseline to post-remission, and to compare these biomarkers between patients who achieve successful remission and those who do not.
Why this matters
A prospective Chinese real-world cohort will test whether type 2 diabetes remission slows epigenetic aging, primarily via DunedinPACE, versus non-remitters.